Zobrazeno 1 - 10
of 1 976
pro vyhledávání: ''
Autor:
Thi-Van-Trinh Tran, Carole Rubino, Rodrigue Allodji, Milena Andruccioli, Stéphane Bardet, Ibrahima Diallo, Massimo Dottorini, Jérome Garsi, Per Hall, Michel Henry-Amar, Stephanie Lamart, Françoise Le Thai, Stefan Lönn, Marcel Ricard, Claire Schvartz, Martin Schlumberger, Neige Journy, Florent de Vathaire
Publikováno v:
British Journal of Cancer. 127:2118-2124
Female thyroid cancer survivors are more likely to have a higher risk of breast cancer compared to the general population, and the underlying causes are yet to be understood. The potential role of I-131 treatment on this association remains controver
Autor:
Sweety Gupta, Sumit Singh, Atokali Chophy, Sharanya Nair, Rachit Ahuja, K. Kusum, Deepa Joseph, Rajnish Arora, Amit Gupta, Manoj Gupta
Publikováno v:
Journal of the Egyptian National Cancer Institute. 34
Introduction Brain metastases (BM) are associated with dismal prognosis as they cause significant morbidity and affect the quality of life of patients. Management of BM depends on the following factors: age, patient performance, size and the number o
Autor:
Zahra Madjd, Mahdieh Razmi, Sima Saki, Elham Kalantari, Leili Saeednejad Zanjani, Monireh Mohsenzadegan, Fahimeh Fattahi, Maryam Abolhasani
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:609-631
Melanoma-associated antigen A2 (MAGE-A2) is a member of the cancer-testis antigen family differentially overexpressed in a variety of malignancies and is associated with tumor development. However, clinical significance and prognostic value of MAGE-A
Autor:
Nassim Djebli, Pierre-Olivier Tremblay, Vincent Buchheit, Mario González-Sales, Guillaume Bonnefois, Georgina Meneses-Lorente, Francois Mercier, Nicolas Frey
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:997-1007
Entrectinib (ROZLYTREK®) is a CNS-active, potent, and selective inhibitor of ROS1, TRK A/B/C, and ALK kinase activity. It was recently approved for the treatment of ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.
Autor:
Michael Thomas, Maria Palmisano, Mark Thomas, Sekhar Surapaneni, Yongjun Xue, Mary Liu, Simon Zhou, Rebecca N. Wood-Horrall, Gopal Krishna, Liangang Liu, Leonidas N Carayannopoulos, Ken Ogasawara
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:941-952
Fedratinib, an oral, selective Janus kinase 2 inhibitor, has been shown to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT) 2, and mul
Publikováno v:
Leukemia
Data from 1661 consecutive subjects with chronic-phase chronic myeloid leukemia (CML) receiving initial imatinib (n = 1379) or a 2nd-generation tyrosine-kinase inhibitor (2G-TKI; n = 282) were interrogated to determine whether the Sokal or European T
Autor:
Mohammed, Safi, Chenxing, Jin, Abdullah, Aldanakh, Ping, Feng, Henan, Qin, Mohammed, Alradhi, Lizhi, Zhang, Junying, Zhang, Salah, Adlat, Yi, Zhao, Jiwei, Liu
Publikováno v:
BMC Cancer. 22
Background Cancer diagnoses and deaths among the elderly (65 +) are expected to increase significantly over the next decade. Immune checkpoint inhibitors specifically target ICI genes and enhance immune system function. However, poor outcomes may be
Autor:
Janos Szederjesi, László Kóbori, Ioan Jung, Decebal Fodor, Haruhiko Sugimura, Simona Gurzu, Rita Szodorai, Cornelia Braicu
Publikováno v:
Histochemistry and Cell Biology. 156:377-390
In hepatocellular carcinomas (HCCs), the role of the cell surface protein V-set and immunoglobulin domain containing 1 (VSIG1), which is known as a specific marker of the gastric mucosa and testis, has not yet been determined. We examined VSIG1 immun
Autor:
Martha A. Zeiger, Zhiyang Liu, Brittany A. McKelvey, Leslie Cope, Christopher B. Umbricht, Yongchun Wang, Lisa M. Rooper
Publikováno v:
J Cancer Res Clin Oncol
BACKGROUND: While molecular testing is a promising strategy for preoperative assessment of cytologically indeterminate thyroid nodules, thyroid fine needle aspiration biopsy (FNA) presents unique challenges for molecular assays, including contaminati
Autor:
Shengmin Chen, Weifeng Wang, Huanliang Wu, Feng Yuan, Zhiren Lin, Gang Cheng, Shaohua Peng, Yunxiu Luo
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:2913-2922
Assessing the downstaging effects of neoadjuvant chemotherapy (NACT) in patients with locally advanced nasopharyngeal carcinoma (LANPC) and predicting response to treatment remain challenging. The present study aimed to evaluate the long-term prognos